ILM1 Antibody

What is IL-1R7 and what role does it play in inflammatory signaling?

IL-1R7, also known as IL-18 receptor beta chain, functions as a co-receptor that forms a critical component of the IL-18 signaling pathway. When mature IL-18 binds to IL-1R5 (IL-18 receptor alpha chain) with relatively low affinity, IL-1R7 joins to create a high-affinity ternary complex that initiates downstream inflammatory signaling cascades. IL-1R7 serves as the sole accessory chain for IL-1R5 and is essential for effective IL-18-mediated immune responses .

The IL-18 signaling system consists of several components, including:

• IL-18: A member of the IL-1 family, synthesized as an inactive precursor and activated by caspase-1 cleavage

• IL-1R5: The primary ligand-binding chain for IL-18

• IL-1R7: The co-receptor required for high-affinity binding and signal transduction

• IL-18BP: A natural inhibitor that regulates IL-18 activity in healthy conditions

This signaling pathway plays a crucial role in various inflammatory conditions, including macrophage activation syndrome (MAS) and certain manifestations of COVID-19 .

What distinguishes anti-IL-1R7 antibody therapy from other approaches to modulating IL-18 signaling?

Anti-IL-1R7 antibody therapy represents a highly specific approach to modulating IL-18-mediated inflammation compared to other strategies. Unlike broader immunosuppressive treatments, anti-IL-1R7 antibodies selectively inhibit IL-18 signaling by targeting the receptor complex rather than the cytokine itself .

Key distinctions include:

• Specificity: Anti-IL-1R7 targets the co-receptor essential for IL-18 signaling, providing selective modulation of this pathway

• Comparability to IL-18BP: While natural IL-18BP directly binds IL-18 with high affinity, anti-IL-1R7 inhibits receptor complex formation

• Broader suppression of inflammatory cascades: Studies show anti-IL-1R7 effectively inhibits LPS-induced IFNγ with efficacy comparable to IL-18BP, suggesting it addresses both direct and indirect activation of inflammatory pathways

When compared to directly targeting IL-18, the anti-IL-1R7 approach may offer advantages in scenarios where IL-18 levels are particularly elevated or where multiple inflammatory pathways are activated simultaneously .

What experimental models are most effective for evaluating anti-IL-1R7 antibody efficacy?

Based on extensive research, several experimental models have proven valuable for assessing anti-IL-1R7 antibody efficacy in both in vitro and in vivo settings:

In vitro models:

• Mouse splenocyte cultures stimulated with IL-12/IL-18 or LPS

• Peritoneal cell cultures for evaluating IFNγ suppression

• IL-1R7-transfected HEK293 cells for antibody binding studies

In vivo models:

• P. acnes/LPS-induced liver injury model: The classic model in which IL-18 was initially identified as an IFNγ-inducing factor. This model generates robust systemic inflammation and significant liver damage, making it ideal for evaluating anti-inflammatory interventions .

• LPS-induced acute lung injury model: Provides insights into the role of anti-IL-1R7 in protecting against inflammatory cell infiltration and cytokine production in pulmonary tissue .

These models enable comprehensive evaluation of antibody efficacy across different inflammatory conditions and organ systems, with endpoints including cytokine levels, tissue pathology, and inflammatory markers .

How does anti-IL-1R7 treatment affect cytokine networks in inflammatory conditions?

In the P. acnes/LPS model, anti-IL-1R7 pretreatment:

• Markedly suppressed plasma IFNγ levels compared to control groups

• Significantly reduced plasma TNFα, IL-1β, and IL-6 concentrations

• Decreased chemokines like MIP-2, indicating reduced neutrophil recruitment

• Lowered ALT levels, suggesting protection against liver injury

In the acute lung injury model, anti-IL-1R7:

• Inhibited inflammatory cell infiltration into lung tissue

• Suppressed production of multiple inflammatory mediators

• Modulated both local and systemic inflammatory responses

These findings indicate that by blocking the IL-18/IL-1R7 axis, anti-IL-1R7 treatment can disrupt the inflammatory cascade at an early point, preventing the amplification of inflammatory signals and protecting against tissue damage .

What are the potential clinical applications of anti-IL-1R7 antibodies for IL-18-mediated diseases?

Research suggests anti-IL-1R7 antibodies have potential applications in treating several IL-18-mediated inflammatory conditions:

• Macrophage Activation Syndrome (MAS): Characterized by excessive activation of macrophages and T cells with elevated IL-18 levels. Anti-IL-1R7 could interrupt the hyperinflammatory cascade by blocking IL-18 signaling .

• COVID-19 with MAS-like manifestations: Some COVID-19 patients develop hyperinflammation similar to MAS, where IL-18 plays a significant role. Anti-IL-1R7 could potentially modulate this inflammatory response .

• Acute inflammatory conditions with IL-18 involvement: Models like acute lung injury demonstrate that anti-IL-1R7 can reduce inflammatory cell infiltration and cytokine production in affected tissues .

• Liver inflammatory diseases: The P. acnes/LPS model demonstrates protection against liver injury, suggesting potential applications in hepatic inflammatory conditions .

The specificity of anti-IL-1R7 for IL-18 signaling makes it particularly promising for conditions where targeted modulation of this pathway is preferable to broader immunosuppression .

What techniques are optimal for screening and identifying effective anti-IL-1R7 antibodies?

Developing effective anti-IL-1R7 antibodies requires a systematic screening approach employing multiple complementary techniques. Based on research protocols, the following methodological sequence has proven successful:

• Initial binding assessment:

  • ELISA-based assays using recombinant IL-1R7 to evaluate binding efficacy

  • Cell-based binding assays using IL-1R7-transfected HEK293 cells to confirm recognition of cell surface-expressed receptors

• Functional screening:

  • Mouse splenocyte cultures stimulated with IL-12/IL-18 to assess inhibition of IFNγ production

  • LPS-stimulated cultures to evaluate effects on indirect IL-18-mediated responses

  • Comparison with IL-18BP as a positive control for IL-18 pathway inhibition

• Antibody optimization:

  • Engineering modifications (e.g., LALA sequence) to prevent triggering of FcγRs

  • Selection based on combined binding efficacy and functional suppression

This comprehensive screening approach enables identification of candidates with optimal properties for both in vitro and in vivo applications, ensuring selection of antibodies that effectively block IL-18 signaling without triggering unwanted immune responses .

What parameters should be measured to evaluate anti-IL-1R7 efficacy in preclinical models?

Comprehensive evaluation of anti-IL-1R7 efficacy in preclinical models requires assessment of multiple parameters across different biological compartments:

Systemic inflammation markers:

• Plasma levels of inflammatory cytokines (IFNγ, TNFα, IL-1β, IL-6)

• Chemokines associated with inflammatory cell recruitment (MIP-2, MIP-1β, IP-10, MCP-1)

• Changes in circulating inflammatory cells (WBC counts and differential)

Tissue-specific assessments:

• Markers of tissue damage (e.g., ALT for liver injury)

• Histopathological evaluation of affected tissues

• Inflammatory cell infiltration (neutrophils, macrophages, lymphocytes)

• Ex vivo cytokine production from isolated tissue cells

Functional outcomes:

• Physiological parameters (temperature, weight changes)

• Organ function tests specific to the model being used

• Survival in severe inflammatory models

The combination of these parameters provides a comprehensive picture of antibody efficacy, helping to distinguish direct effects on IL-18 signaling from broader impacts on inflammatory cascades and tissue protection .

How should researchers design dose-finding studies for anti-IL-1R7 antibodies?

Designing effective dose-finding studies for anti-IL-1R7 antibodies requires careful consideration of multiple factors to determine optimal dosing regimens for different experimental conditions:

• Preliminary binding studies:

  • Establish dose-response relationships for receptor binding in vitro

  • Determine EC50 values for functional effects in cell-based assays

  • Compare potency with reference inhibitors like IL-18BP

• In vivo dose-ranging:

  • Test multiple dose levels with appropriate spacing (typically 2-3 fold differences)

  • Consider both pre-treatment and intervention models to assess preventive vs. therapeutic effects

  • Include pharmacokinetic assessments to understand antibody distribution and clearance

• Parameter selection:

  • Primary endpoints should include direct markers of IL-18 pathway inhibition (e.g., IFNγ levels)

  • Secondary endpoints should assess broader inflammatory effects and tissue protection

  • Include time-course studies to determine optimal timing of administration relative to inflammatory challenge

• Analytical approach:

  • Establish clear dose-response relationships for key parameters

  • Determine minimum effective dose and plateau effects

  • Evaluate therapeutic window between efficacy and any potential adverse effects

This systematic approach ensures identification of optimal dosing regimens for different experimental models and provides critical data for translating findings toward potential clinical applications .

What are the prospects for developing humanized anti-IL-1R7 antibodies for clinical trials?

The development of mouse anti-IL-1R7 antibodies with demonstrated efficacy in preclinical models lays groundwork for humanized versions suitable for clinical trials. Previous work has already established a humanized monoclonal anti-IL-1R7 antibody (anti-hIL-1R7) with promising therapeutic potential that suppressed IL-18-mediated pro-inflammatory signaling in primary human cell cultures .

Key considerations for clinical translation include:

• Humanization strategies:

  • CDR grafting onto human antibody frameworks

  • Optimization to maintain binding affinity while minimizing immunogenicity

  • Engineering modifications (such as the LALA mutations) to prevent unwanted Fc-mediated effects

• Target patient populations:

  • Patients with MAS or MAS-like manifestations of COVID-19

  • Individuals with other IL-18-mediated inflammatory diseases

  • Conditions where current therapies have limited efficacy

• Biomarker development:

  • Identification of IL-18 pathway activation markers to select appropriate patients

  • Development of assays to monitor treatment efficacy

  • Correlation of biomarker changes with clinical outcomes

The successful preclinical validation in multiple inflammatory models suggests anti-IL-1R7 antibodies represent a promising therapeutic strategy warranting further investigation in clinical settings .

How might anti-IL-1R7 therapy compare with other cytokine-targeting approaches in inflammatory diseases?

Anti-IL-1R7 therapy offers distinct advantages and potential complementary effects compared to other cytokine-targeting approaches in inflammatory diseases:

• Compared to direct IL-18 neutralization:

  • Targets the signaling receptor rather than the cytokine

  • May be more effective in conditions with extremely high IL-18 levels that could overwhelm direct neutralization approaches

  • Potentially affects a broader range of IL-18-dependent responses

• Compared to IL-1 blockade:

  • More specific for IL-18-mediated pathways

  • May have different efficacy profile in conditions where IL-18 plays a dominant role

  • Could be combined with IL-1 blockade for synergistic effects in conditions where both pathways contribute

• Compared to TNFα inhibitors:

  • Acts upstream in the inflammatory cascade in certain conditions

  • Research shows anti-IL-1R7 reduces TNFα production, suggesting it addresses an earlier point in the inflammatory sequence

  • May offer benefit in TNF-inhibitor resistant cases where IL-18 drives inflammation

• Potential for combination therapy:

  • Rational combinations targeting different inflammatory pathways

  • Sequential therapy based on disease evolution

  • Personalized approaches based on cytokine profiles

This unique position in the inflammatory cascade makes anti-IL-1R7 a valuable addition to the therapeutic arsenal, with potential advantages in specific inflammatory conditions driven primarily by IL-18 .

What further studies are needed to fully characterize the long-term effects of IL-18 pathway modulation?

While current research demonstrates promising acute anti-inflammatory effects of anti-IL-1R7 antibodies, several key areas require further investigation to fully characterize long-term effects and optimize clinical applications:

• Extended safety evaluation:

  • Assessment of prolonged IL-18 pathway inhibition on immune surveillance

  • Monitoring for potential compensatory increases in other inflammatory pathways

  • Evaluation of impact on beneficial IL-18 functions in host defense

• Chronic disease models:

  • Testing in models of persistent inflammation beyond acute challenges

  • Evaluation of efficacy with repeated dosing over extended periods

  • Assessment of potential tachyphylaxis or receptor up-regulation

• Combination therapy studies:

  • Systematic evaluation of synergies with other anti-inflammatory approaches

  • Determination of optimal sequencing and dosing in combination regimens

  • Identification of biomarkers predictive of combination efficacy

• Mechanistic investigations:

  • Deeper analysis of downstream signaling pathways affected by IL-1R7 blockade

  • Transcriptomic and proteomic studies to identify broader effects on inflammatory networks

  • Investigation of cell type-specific responses to IL-18 pathway inhibition

• Translational biomarkers:

  • Development of companion diagnostics to identify patients most likely to benefit

  • Validation of surrogate markers for early efficacy assessment

  • Identification of markers predictive of sustained response

These additional studies will provide crucial insights for optimizing anti-IL-1R7 therapy and further defining its role in the treatment landscape for inflammatory conditions .